Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer

Journal of Clinical Oncology

Volumn 20, Issue 16, 2002, Pages 3508-3521

  Raymond, E ^a   ten Bokkel Huinink, W W ^a   Taieb J ^a   Beijnen, J H ^a   Faivre, S ^a   Wanders, J ^a   Ravic, M ^a   Fumoleau, P ^a   Armand, J P ^a   Schellens, J H M ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INDISULAM; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STRUCTURE; FATIGUE; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; SULFONAMIDES;

EID: 0037102283     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.09.030     Document Type: Article

References (38)

1. Cancer cell cycles
2. The Pezcoller lecture: Cancer cell cycles revisited
3. Preclinical and clinical development of cyclin-dependent kinase modulators
4. Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target
5. Chemical inhibitors of cyclin-dependent kinases
6. Properties and potential applications of chemical inhibitors of cyclin-dependent kinases
7. Cyclin-dependent kinase inhibitors: Novel anticancer agents
8. A novel antitumor agent ER-35744, targeting G1 phase I: Discovery and structure-activity relationships
9. Microarray based expression profiling of sulfonamide antitumor agents
10. A novel antitumor agent ER-35744, targeting G1 phase III: Studies of mechanism of action
11. Antitumor effects of E7070 (ER-35744) against orthotopically transplanted mouse and human colorectal tumors
12. A novel agent ER-35744, targeting G1 phase II: Antitumor activities in vitro and in vivo
13. The NCI anti-cancer drug screen: A smart screen to identify effectors of novel targets
14. Immunosuppressive properties of chloroquinoxaline sulfonamide
15. Chloroquinoxaline sulfonamide: A sulfanilamide antitumor agent entering clinical trials
16. Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule
17. Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide
18. Cellular pharmacology of chloroquinoxaline sulfonamide and a related compound in murine B 16 melanoma cells
19. CDK inhibitors: Positive and negative regulators of G1-phase progression
20. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: Current status
21. Flavopiridol: The first cyclin-dependent kinase inhibitor in human clinical trials
22. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea
23. Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol
24. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma
25. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
26. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer
27. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago phase II consortium study
28. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alphal-acid glycoprotein
29. Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models
30. UCN-01: A potent abrogator of G 2 checkpoint function in cancer cells with disrupted p53
31. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms
32. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle
33. Cell cycle regulation in the g1 phase: A promising target for the development of new chemotherapeutic anticancer agents
34. Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells
35. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors: A study by the EORTC-early clinical studies group (ECSG)
36. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo
37. Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070, a novel chloroindolyl-sulfonamide inhibiting the activation of cdk2 and cyclin E